Atossa Genetics Conference Call and Webcast Notice

(firmenpresse) - SEATTLE, WA -- (Marketwired) -- 10/04/13 -- (NASDAQ: ATOS), The Breast Health Company™, will host a conference call at 5:45 pm Eastern Time today to discuss the Company's voluntary recall of its ForeCYTE Breast Health Test; Mammary Aspiration Specimen Cytology Test (MASCT) System, which was announced today at 5:00 pm Eastern Time.

To listen to the call by phone, interested parties within the U.S. may dial 866-652-5200. International callers should dial 412-317-6060. All callers should ask for the Atossa Genetics conference call. The conference call will also be available through a live webcast at .

A replay of the call will be available one hour after the end of the call through November 4, 2013, and can be accessed via Atossa's website or by dialing 877-344-7529 (domestic) or 412-317-0088 (international). The replay conference ID number is 10034877.



Atossa Genetics, Inc. is focused on the commercialization of patented, diagnostic medical devices and, through its wholly-owned subsidiary, The National Reference Laboratory for Breast Health, Inc. (NRLBH), patented, laboratory developed tests designed to assess breast health.

The NRLBH is a CLIA-certified high-complexity molecular diagnostic laboratory located in Seattle, Washington.

For additional information, on Atossa and the NRLBH, please visit and .



Atossa Genetics, Inc.
Kyle Guse
CFO and General Counsel
(O) 800-351-3902


MBS Value Partners
Matthew D. Haines (Investors)
Managing Director
(O) 212-710-9686


JQA Partners
Jules Abraham (Media)
Principal
917-885-7378

Weitere Infos zu dieser Pressemeldung:

Themen in dieser Pressemitteilung:


Unternehmensinformation / Kurzprofil:
Bereitgestellt von Benutzer: Marketwired
Datum: 04.10.2013 - 21:01 Uhr
Sprache: Deutsch
News-ID 303038
Anzahl Zeichen: 0

contact information:
Town:

SEATTLE, WA

Kategorie:

Healthcare

Diese Pressemitteilung wurde bisher 272 mal aufgerufen.


Die Pressemitteilung mit dem Titel:
"Atossa Genetics Conference Call and Webcast Notice"
steht unter der journalistisch-redaktionellen Verantwortung von

Atossa Genetics, Inc. (Nachricht senden)

Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).

Atossa Genetics Announces Warrant Exercises ...

SEATTLE, WA -- (Marketwired) -- 06/30/17 -- Atossa Genetics Inc. (NASDAQ: ATOS), a clinical-stage pharmaceutical company developing novel therapeutics and delivery methods for breast cancer and other breast conditions, today announced that holders o ...

Atossa Genetics Receives Positive Safety Committee Assessment of First Cohort Re ...

SEATTLE, WA -- (Marketwired) -- 06/26/17 -- Atossa Genetics Inc. (NASDAQ: ATOS), a clinical-stage pharmaceutical company developing novel therapeutics and delivery methods to treat breast cancer and other breast conditions, today announced that it h ...

Atossa Genetics to Present at the LD Micro Invitational on June 6, 2017 ...

SEATTLE, WA -- (Marketwired) -- 06/01/17 -- Atossa Genetics, Inc. (NASDAQ: ATOS), a clinical-stage pharmaceutical company developing novel therapeutics and delivery methods for breast cancer and other breast conditions, today announced that Kyle Gus ...

Alle Meldungen von Atossa Genetics, Inc.